The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Abstract
Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural killer (NK)-cell–activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fcγ-receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen, respectively. Median counts of NK cells and of all lymphocyte subsets were considerably decreased in the patients before therapy. HRS-3/A9 was administered 4 times every 3 to 4 days, starting with 1 mg/m2. The treatment was well tolerated, and the maximum tolerated dose was not reached at 64 mg/m2, the highest dose administered because of the limited amounts of HRS-3/A9 available. Side effects were rare and consisted of fever, pain in involved lymph nodes, and a maculopapulous rash. A total of 9 patients developed human antimouse Ig antibodies, and 4 patients developed an allergic reaction after attempted retreatment. A total of 1 complete and 1 partial remission (lasting 16 and 3 months, respectively), 3 minor responses (1 to 11+ months), and 1 mixed response were achieved. There was no clear-cut dose-side effect or dose-response correlation. Our results encourage further clinical trials with this novel immunotherapeutic approach and emphasize the necessity to reduce the immunogenicity of the murine bispecific antibodies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two Phase 1 clinical studies performed with this molecule led to one complete remission (CR) and one partial remission (PR) in a group of 15 treated patients; 14 this was followed by one CR and three PR in a second clinical trial. 15”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [14]
Citations
Cites
Stein, H., Mason, D., Gerdes, J., O'Connor, N., Wainscoat, J. S., Pallesen, G., Gatter, K. C., Falini, B., Delsol, G., Lemke, H., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.848 · Cited by 1,849
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 882
Stein, H., Mason, D., Gerdes, J., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.bloodjournal664848 · Cited by 717
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 525
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351
Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E. S., Cochran, K., Cameron, C. A., Schow, P. W., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 267
Preliminary trial of specific targeting therapy against malignant glioma
Nitta, T., Yagita∥, H., Okumura, K., Sato, K., & Ishii, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90205-j · Cited by 235
Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Re, E. D., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1463 · Cited by 187
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V. A., Deo, Y. M., Graziano, R. F., Fisher, J. L., Meyer, L. A., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180
Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
Renner, C., Jung, W. E., Şahin, U., Denfeld, R. W., Pohl, C., Trümper, L. H. P., Hartmann, F., Diehl, V., van Lier, R. A. W., & Pfreundschuh, M. G. (1994) · Science · doi:10.1126/science.8171337 · Cited by 156
Self-citationPhase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner, L. M., Clark, J. I., Davey, M., Li, W. S., de Palazzo, I. G., Ring, D. B., & Alpaugh, R. K. (1995) · PubMed · Cited by 139
Antibodies as cytotoxic therapy.
Dillman, R. O. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.7.1497 · Cited by 126
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
Bolhuis, R. L. H., Lamers, C. H., Goey, S. H., Eggermont, A. M. M., Trimbos, J. B. M. Z., Stoter, G., Lanzavecchia, A., Re, E. D., Miotti, S., & Raspagliesi, F. (1992) · PubMed · Cited by 108
The impact of Hodgkin's disease on the immune system.
Slivnick, D. J., Ellis, T. M., Nawrocki, J. F., & Fisher, R. I. (1990) · PubMed · Cited by 87
Elsässer, D., Valerius, T., Repp, R., Weiner, G. J., Deo, Y. M., Kalden, J., van de Winkel, J. G. J., Stevenson, G., Glennie, M. J., & Gramatzki, M. (1996) · Blood · doi:10.1182/blood.v87.9.3803.bloodjournal8793803 · Cited by 86
Hombach, A. A., Jung, W. E., Pohl, C., Renner, C., Şahin, U., Schmits, R., Wolf, J., Kapp, U., Diehl, V., & Pfreundschuh, M. G. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550523 · Cited by 85
Self-citationKroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R., van der Graaf, W., The, T., de Leij, L., & Mulder, N. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.366 · Cited by 82
Maskens, A. P., & Dujardin‐Loits, R. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 75
Kroesen, B., ter Haar, A., Spakman, H., Willemse, P. H. B., Sleijfer, D. T., de Vries, E. G. E., Mulder, N. H., Berendsen, H. H., Limburg, P. C., THE, T. H., et al. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01526797 · Cited by 64
Ely, P., Wallace, P. K., Givan, A. L., Graziano, R. F., Guyre, P. M., & Fanger, M. W. (1996) · Blood · doi:10.1182/blood.v87.9.3813.bloodjournal8793813 · Cited by 58
Tumor Therapy by Immune Recruitment with Bispecific Antibodies
Renner, C., & Pfreundschuh, M. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00082.x · Cited by 58
Self-citationGAST, G. C. D., Haagen, I.-A., van Houten, A. A., Klein, S. C., Duits, A. J., de Weger, R. A., Feltkamp‐Vroom, T. M., Clark, M., Phillips, J. M., van Dijk, A. J. G., et al. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01525390 · Cited by 49
Demanet, C., Brissinck, J., Jonge, J. D., & Thielemans, K. (1996) · Blood · doi:10.1182/blood.v87.10.4390.bloodjournal87104390 · Cited by 47
Lamers, C. H. J., Gratama, J. W., Warnaar, S. O., Stoter, G., & Bolhuis, R. L. H. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600405 · Cited by 46
Fanger, M. W., Morganelli, P. M., & Guyre, P. M. (2025) · Reactions Weekly · doi:10.1007/s40278-025-91226-9 · Cited by 36
Renner, C., Bauer, S., Şahin, U., Jung, W. E., van Lier, R. A. W., Jacobs, G., Held, G., & Pfreundschuh, M. G. (1996) · Blood · doi:10.1182/blood.v87.7.2930.bloodjournal8772930 · Cited by 34
Self-citationŞahin, U., Kraft-Bauer, S., Ohnesorge, S., Pfreundschuh, M., & Renner, C. (1996) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050245 · Cited by 25
Self-citationPohl, C., Renner, C., Schwonzen, M., Sieber, M., Lorenz, P., Pfreundschuh, M. G., & Diehl, V. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500623 · Cited by 19
Self-citationReilly, R. M., Kirsh, J. C., Gallinger, S., Thiessen, J. J., Damani, M., Hay, K., Polihronis, J., Schmocker, B., Odze, R. D., Houle, S., et al. (1993) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(93)90136-i · Cited by 7
Research works printed but not linked: 1
- Weiner, 1995, Phase I Trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FcγRIII., Cancer Res, 55, 4586
Cited by
Sorted by citations
Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., Boissevain, F., Zschaber, R., Müller, P. E., Kirchner, H. H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08938-9 · Cited by 1,134
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,081
Löffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445
Gessner, J. E., Heiken, H., Tamm, A., & Schmidt, R. E. (1998) · Annals of Hematology · doi:10.1007/s002770050396 · Cited by 410
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Metadata
- Authors
- Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-03-15
- Volume
- 89
- Issue
- 6
- Pages
- 2042-2047
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1539079695
- Cited by
- 149
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 7
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- refractory Hodgkin lymphoma, bispecific antibodies, CD16, CD30, NK cell activation, Fc gamma receptor III, immunotherapy, maximum tolerated dose, human anti-mouse antibodies, immunogenicity, allergic reactions, treatment response
- MeSH terms
- Adolescent, Adult, Antibodies, Monoclonal, Female, Hodgkin Disease, Humans, Male, Middle Aged, Remission Induction, Lymphocyte Subsets, Receptors, IgG, Ki-1 Antigen, Antibodies, Bispecific, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
